• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Complaints upheld after Saxenda adverts appear on Instagram

8th October 2020 by PIP editor Leave a Comment

 

Three organisations have been found by the Advertising Standards Agency (ASA) to have broken advertising rules by advertising the prescription-only medicine Saxenda to the general public. In the UK it is illegal to advertise prescription-only medicines to the general public.

 

The breaches included the following:

 

  • Four Instagram posts by Skinny Revolution Ltd, a weight loss injection provider.
  • Two Instagram posts and a website for SkinnyJab Ltd, a weight loss injection provider.
  • Three Instagram posts and a website for Skinny Clinic, a weight loss injection provider.

 

There were quite a number of issues raised by the ASA including the irresponsible promotion of the weight loss product Saxenda. All of the issues raised were upheld by the ASA and all three companies were found to have used Instagram to advertise the prescription-only medicine Saxenda.

 

The ASA told Skinny Revolution that the ads must not appear again in their current form. They told Skinny Revolution Ltd not to make claims that people could lose a precise amount of weight within a stated period and to ensure that claims that an individual had lost an exact amount of weight were compatible with good medical and nutritional practice. They also asked them to ensure they did not promote prescription-only medicines to the general public. They further told Skinny Revolution Ltd to ensure the presentation of their ads did not irresponsibly exploit people’s insecurities around body image.

 

The ASA told SkinnyJab Ltd that the ads must not appear again in their current form. They told SkinnyJab Ltd to ensure they did not promote prescription-only medicines to the general public. The ASA told SkinnyJab Ltd and Gemma Collins to ensure that their ads were obviously identifiable as marketing communications for example, by including a clear and prominent identifier such as #ad. The ASA further told SkinnyJab to ensure their ads did not irresponsibly imply that it could be used by people who were not overweight and suggest uses outside the summary of product characteristics for a licenced medicine. They also told them not to make claims that people could lose a precise amount of weight within a stated period.

 

The ASA told Skinny Clinic that the ads must not appear again in their current form. They told Skinny Clinic not to make claims that people could lose a precise amount of weight within a stated period. The ASA also told Skinny Clinic to ensure their ads did not irresponsibly imply that their products could be used by people who were not overweight and suggest uses outside the summary of product characteristics for a licenced medicine. We further told them not to promote prescription-only medicines to the general public in future.

 

You can read about the cases in more detail here.

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  £5million invested in community pharmacy delivery service

Filed Under: News Tagged With: Advertising, ASA, Weight loss

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Excessive accumulation of medication at home is common

Is there a pragmatic way through the provisional registration problem?

Pharmacies should be allowed to supply rapid antibody tests

No national Scottish pharmacy flu service a missed opportunity

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.